|
1
|
Xiao W, Dai B, Zhu Y and Ye D:
Norcantharidin induces autophagy-related prostate cancer cell death
through Beclin-1 upregulation by miR-129-5p suppression. Tumour
Biol. Dec 5–2015.Epub ahead of print.
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Utomo NB, Mochtar CA and Umbas R: Primary
hormonal treatment in localized and locally advanced prostate
cancer: Effectiveness and survival predictive factors. Acta Med
Indones. 44:10–15. 2012.PubMed/NCBI
|
|
4
|
Dasgupta S, Srinidhi S and Vishwanatha JK:
Oncogenic activation in prostate cancer progression and metastasis:
Molecular insights and future challenges. J Carcinog. 11:42012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fraser M, Berlin A, Bristow RG and van der
Kwast T: Genomic, pathological, and clinical heterogeneity as
drivers of person-alized medicine in prostate cancer. Urol Oncol.
33:85–94. 2015. View Article : Google Scholar
|
|
6
|
Fabris L, Ceder Y, Chinnaiyan AM, Jenster
GW, Sorensen KD, Tomlins S, Visakorpi T and Calin GA: The potential
of microRNAs as prostate cancer biomarkers. Eur Urol. 70:312–322.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Porkka KP, Pfeiffer MJ, Waltering KK,
Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression
profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Srivastava A, Goldberger H, Dimtchev A,
Ramalinga M, Chijioke J, Marian C, Oermann EK, Uhm S, Kim JS, Chen
LN, et al: MicroRNA profiling in prostate cancer - the diagnostic
potential of urinary miR-205 and miR-214. PLoS One. 8:e769942013.
View Article : Google Scholar :
|
|
9
|
Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu
M, Tepper CG, Evans CP, Kung HJ and deVere White RW: An
androgen-regulated miRNA suppresses Bak1 expression and induces
androgen-independent growth of prostate cancer cells. Proc Natl
Acad Sci USA. 104:19983–19988. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsu TI, Hsu CH, Lee KH, Lin JT, Chen CS,
Chang KC, Su CY, Hsiao M and Lu PJ: MicroRNA-18a is elevated in
prostate cancer and promotes tumorigenesis through suppressing STK4
in vitro and in vivo. Oncogenesis. 3:e992014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Li B, Li L and Wang T:
MicroRNA-497 suppresses proliferation and induces apoptosis in
prostate cancer cells. Asian Pac J Cancer Prev. 14:3499–3502. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nazarov PV, Reinsbach SE, Muller A, Nicot
N, Philippidou D, Vallar L and Kreis S: Interplay of microRNAs,
transcription factors and target genes: Linking dynamic expression
changes to function. Nucleic Acids Res. 41:2817–2831. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cellini F, Morganti AG, Genovesi D,
Silvestris N and Valentini V: Role of microRNA in response to
ionizing radiations: Evidences and potential impact on clinical
practice for radiotherapy. Molecules. 19:5379–5401. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo LJ, Wang DD, Wang J, Yang F and Tang
JH: Diverse roles of miR-335 in development and progression of
cancers. Tumour Biol. 37:1–12. 2016. View Article : Google Scholar
|
|
15
|
Tavazoie SF, Alarcón C, Oskarsson T, Padua
D, Wang Q, Bos PD, Gerald WL and Massagué J: Endogenous human
microRNAs that suppress breast cancer metastasis. Nature.
451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang F, Zheng Z, Guo J and Ding X:
Correlation and quanti-tation of microRNA aberrant expression in
tissues and sera from patients with breast tumor. Gynecol Oncol.
119:586–593. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shu M, Zheng X, Wu S, Lu H, Leng T, Zhu W,
Zhou Y, Ou Y, Lin X, Lin Y, et al: Targeting oncogenic miR-335
inhibits growth and invasion of malignant astrocytoma cells. Mol
Cancer. 10:592011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dohi O, Yasui K, Gen Y, Takada H, Endo M,
Tsuji K, Konishi C, Yamada N, Mitsuyoshi H, Yagi N, et al:
Epigenetic silencing of miR-335 and its host gene MEST in
hepatocellular carcinoma. Int J Oncol. 42:411–418. 2013. View Article : Google Scholar :
|
|
20
|
Shi L, Jiang D, Sun G, Wan Y, Zhang S,
Zeng Y, Pan T and Wang Z: miR-335 promotes cell proliferation by
directly targeting Rb1 in meningiomas. J Neurooncol. 110:155–162.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fu Q, Liu X, Liu Y, Yang J, Lv G and Dong
S: MicroRNA-335 and -543 suppress bone metastasis in prostate
cancer via targeting endothelial nitric oxide synthase. Int J Mol
Med. 36:1417–1425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun Z, Zhang Z, Liu Z, Qiu B and Liu K:
MicroRNA-335 inhibits invasion and metastasis of colorectal cancer
by targeting ZEB2. Med Oncol. 31:9822014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Heyn H, Engelmann M, Schreek S, Ahrens P,
Lehmann U, Kreipe H, Schlegelberger B and Beger C: MicroRNA miR-335
is crucial for the BRCA1 regulatory cascade in breast cancer
development. Int J Cancer. 129:2797–2806. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao Y, Zeng F, Wu JY, Li HY, Fan JJ, Mai
L, Zhang J, Ma DM, Li Y and Song FZ: miR-335 inhibits migration of
breast cancer cells through targeting oncoprotein c-Met. Tumour
Biol. 36:2875–2883. 2015. View Article : Google Scholar
|
|
25
|
Zhang S, Xia C, Xu C, Liu J, Zhu H, Yang
Y, Xu F, Zhao J, Chang Y and Zhao Q: Early growth response 3
inhibits growth of hepatocellular carcinoma cells via upregulation
of Fas ligand. Int J Oncol. 50:805–814. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bhattacharyya S, Fang F, Tourtellotte W
and Varga J: Egr-1: New conductor for the tissue repair orchestra
directs harmony (regeneration) or cacophony (fibrosis). J Pathol.
229:286–297. 2013. View Article : Google Scholar
|
|
27
|
Bolli N, Avet-Loiseau H, Wedge DC, Van Loo
P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S,
Bignell GR, et al: Heterogeneity of genomic evolution and
mutational profiles in multiple myeloma. Nat Commun. 5:29972014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boone DN, Qi Y, Li Z and Hann SR: Egr1
mediates p53-independent c-Myc-induced apoptosis via a noncanonical
ARF-dependent transcriptional mechanism. Proc Natl Acad Sci USA.
108:632–637. 2011. View Article : Google Scholar
|
|
29
|
Wirth M, Stojanovic N, Christian J, Paul
MC, Stauber RH, Schmid RM, Häcker G, Krämer OH, Saur D and
Schneider G: MYC and EGR1 synergize to trigger tumor cell death by
controlling NOXA and BIM transcription upon treatment with the
proteasome inhibitor bortezomib. Nucleic Acids Res. 42:10433–10447.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salotti J, Sakchaisri K, Tourtellotte WG
and Johnson PF: An Arf-Egr-C/EBPβ pathway linked to ras-induced
senescence and cancer. Mol Cell Biol. 35:866–883. 2015. View Article : Google Scholar :
|
|
31
|
Pio R, Jia Z and Baron VT: Early growth
response 3 (Egr3) is highly over-expressed in non-relapsing
prostate cancer but not in relapsing prostate cancer. PLoS One.
8:e540962013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Baron VT, Pio R, Jia Z and Mercola D:
Early growth response 3 regulates genes of inflammation and
directly activates IL6 and IL8 expression in prostate cancer. Br J
Cancer. 112:755–764. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)). Method Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
34
|
National Research Council: Guide for the
Care and Use of Laboratory Animals. 8th edition. The National
Academies Press; Washington, DC: 2011
|
|
35
|
Liao F, Ji MY, Shen L, Qiu S, Guo XF and
Dong WG: Decreased EGR3 expression is related to poor prognosis in
patients with gastric cancer. J Mol Histol. 44:463–468. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang ZD, Qu FY, Chen YY, Ran ZS, Liu HY
and Zhang HD: Involvement of microRNA-718, a new regulator of EGR3,
in regulation of malignant phenotype of HCC cells. J Zhejiang Univ
Sci B. 18:27–36. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hu X, Schwarz JK, Lewis JS Jr, Huettner
PC, Rader JS, Deasy JO, Grigsby PW and Wang X: A microRNA
expression signature for cervical cancer prognosis. Cancer Res.
70:1441–1448. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin M, Chen W, Huang J, Gao H, Ye Y, Song
Z and Shen X: MicroRNA expression profiles in human colorectal
cancers with liver metastases. Oncol Rep. 25:739–747. 2011.
|
|
39
|
Fuse M, Nohata N, Kojima S, Sakamoto S,
Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T,
et al: Restoration of miR-145 expression suppresses cell
proliferation, migration and invasion in prostate cancer by
targeting FSCN1. Int J Oncol. 38:1093–1101. 2011.PubMed/NCBI
|
|
40
|
Kojima S, Chiyomaru T, Kawakami K, Yoshino
H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M, et
al: Tumour suppressors miR-1 and miR-133a target the oncogenic
function of purine nucleoside phosphorylase (PNP) in prostate
cancer. Br J Cancer. 106:405–413. 2012. View Article : Google Scholar :
|
|
41
|
Kojima S, Enokida H, Yoshino H, Itesako T,
Chiyomaru T, Kinoshita T, Fuse M, Nishikawa R, Goto Y, Naya Y, et
al: The tumor-suppressive microRNA-143/145 cluster inhibits cell
migration and invasion by targeting GOLM1 in prostate cancer. J Hum
Genet. 59:78–87. 2014. View Article : Google Scholar
|
|
42
|
Nishimura Y, Takizawa R, Koike S,
Kinoshita A, Satomura Y, Kawasaki S, Yamasue H, Tochigi M, Kakiuchi
C, Sasaki T, et al: Association of decreased prefrontal hemodynamic
response during a verbal fluency task with EGR3 gene polymorphism
in patients with schizophrenia and in healthy individuals.
Neuroimage. 85:527–534. 2014. View Article : Google Scholar
|
|
43
|
Li S, Miao T, Sebastian M, Bhullar P,
Ghaffari E, Liu M, Symonds AL and Wang P: The transcription factors
Egr2 and Egr3 are essential for the control of inflammation and
antigen-induced proliferation of B and T cells. Immunity.
37:685–696. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu D, Evans I, Britton G and Zachary I:
The zinc-finger transcription factor, early growth response 3,
mediates VEGF-induced angiogenesis. Oncogene. 27:2989–2998. 2008.
View Article : Google Scholar
|
|
45
|
Cheng H, Hao S, Liu Y, Pang Y, Ma S, Dong
F, Xu J, Zheng G, Li S, Yuan W, et al: Leukemic marrow infiltration
reveals a novel role for Egr3 as a potent inhibitor of normal
hematopoietic stem cell proliferation. Blood. 126:1302–1313. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Marcucci G, Maharry K, Radmacher MD,
Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus
CD, Liu CG, et al: Prognostic significance of, and gene and
microRNA expression signatures associated with, CEBPA mutations in
cytogenetically normal acute myeloid leukemia with high-risk
molecular features: A Cancer and Leukemia Group B Study. J Clin
Oncol. 26:5078–5087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Soon PS, Tacon LJ, Gill AJ, Bambach CP,
Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson
BG, et al: miR-195 and miR-483-5p identified as predictors of poor
prognosis in adrenocortical cancer. Clin Cancer Res. 15:7684–7692.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang
X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a
metastasis suppressor in gastric cancer by targeting Bcl-w and
specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar :
|
|
49
|
Vickers MM, Bar J, Gorn-Hondermann I,
Yarom N, Daneshmand M, Hanson JE, Addison CL, Asmis TR, Jonker DJ,
Maroun J, et al: Stage-dependent differential expression of
microRNAs in colorectal cancer: Potential role as markers of
metastatic disease. Clin Exp Metastasis. 29:123–132. 2012.
View Article : Google Scholar
|
|
50
|
Olson P, Lu J, Zhang H, Shai A, Chun MG,
Wang Y, Libutti SK, Nakakura EK, Golub TR and Hanahan D: MicroRNA
dynamics in the stages of tumorigenesis correlate with hallmark
capabilities of cancer. Genes Dev. 23:2152–2165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang W, Lee DY and Ben-David Y: The roles
of microRNAs in tumorigenesis and angiogenesis. Int J Physiol
Pathophysiol Pharmacol. 3:140–155. 2011.PubMed/NCBI
|
|
52
|
Polytarchou C, Iliopoulos D and Struhl K:
An integrated transcriptional regulatory circuit that reinforces
the breast cancer stem cell state. Proc Natl Acad Sci USA.
109:14470–14475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu H, Li W, Chen C, Pei Y and Long X:
miR-335 acts as a potential tumor suppressor miRNA via
downregulating ROCK1 expression in hepatocellular carcinoma. Tumour
Biol. 36:6313–6319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang H, Li M, Zhang R, Wang Y, Zang W, Ma
Y, Zhao G and Zhang G: Effect of miR-335 upregulation on the
apoptosis and invasion of lung cancer cell A549 and H1299. Tumour
Biol. 34:3101–3109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yang B, Huang J, Liu H, Guo W and Li G:
miR-335 directly, while miR-34a indirectly modulate survivin
expression and regulate growth, apoptosis, and invasion of gastric
cancer cells. Tumour Biol. 37:1771–1779. 2016. View Article : Google Scholar
|
|
56
|
Scarola M, Schoeftner S, Schneider C and
Benetti R: miR-335 directly targets Rb1 (pRb/p105) in a proximal
connection to p53-dependent stress response. Cancer Res.
70:6925–6933. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Qiao J, Lee S, Paul P, Theiss L, Tiao J,
Qiao L, Kong A and Chung DH: miR-335 and miR-363 regulation of
neuroblastoma tumorigenesis and metastasis. Surgery. 154:226–233.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tomé M, López-Romero P, Albo C, Sepúlveda
JC, Fernández-Gutiérrez B, Dopazo A, Bernad A and González MA:
miR-335 orchestrates cell proliferation, migration and
differentiation in human mesenchymal stem cells. Cell Death Differ.
18:985–995. 2011. View Article : Google Scholar :
|
|
59
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Balkwill FR and Mantovani A:
Cancer-related inflammation: Common themes and therapeutic
opportunities. Semin Cancer Biol. 22:33–40. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shu M, Zhou Y, Zhu W, Zhang H, Wu S, Chen
J and Yan G: MicroRNA 335 is required for differentiation of
malignant glioma cells induced by activation of cAMP/protein kinase
A pathway. Mol Pharmacol. 81:292–298. 2012. View Article : Google Scholar
|
|
62
|
Xiong SW, Lin TX, Xu KW, Dong W, Ling XH,
Jiang FN, Chen G, Zhong WD and Huang J: MicroRNA-335 acts as a
candidate tumor suppressor in prostate cancer. Pathol Oncol Res.
19:529–537. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Suzuki T, Inoue A, Miki Y, Moriya T,
Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S and Sasano
H: Early growth responsive gene 3 in human breast carcinoma: A
regulator of estrogen-meditated invasion and a potent prognostic
factor. Endocr Relat Cancer. 14:279–292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fang F, Shangguan AJ, Kelly K, Wei J,
Gruner K, Ye B, Wang W, Bhattacharyya S, Hinchcliff ME,
Tourtellotte WG, et al: Early growth response 3 (Egr-3) is induced
by transforming growth factor-β and regulates fibrogenic responses.
Am J Pathol. 183:1197–1208. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Gómez-Martín D, Díaz-Zamudio M,
Galindo-Campos M and Alcocer-Varela J: Early growth response
transcription factors and the modulation of immune response:
Implications towards autoimmunity. Autoimmun Rev. 9:454–458. 2010.
View Article : Google Scholar
|
|
66
|
Rojas A, Liu G, Coleman I, Nelson PS,
Zhang M, Dash R, Fisher PB, Plymate SR and Wu JD: IL-6 promotes
prostate tumorigenesis and progression through autocrine
cross-activation of IGF-IR. Oncogene. 30:2345–2355. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Singh RK and Lokeshwar BL: Depletion of
intrinsic expression of Interleukin-8 in prostate cancer cells
causes cell cycle arrest, spontaneous apoptosis and increases the
efficacy of chemotherapeutic drugs. Mol Cancer. 8:572009.
View Article : Google Scholar : PubMed/NCBI
|
